InflaRx NV Stock Quote IFRX - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

1.5085

Bid

1.50

Ask

1.52

Volume

14,669

1.49 Day's Range 1.515

1.14 52 Week Range 2.79

Market Cap

88.825M

Previous Close

1.48

Open

1.49

Last Trade

500

1.5085

Last Trade Time

10:58:31

Financial Volume

$ 22,024

VWAP

1.5014

Average Volume (3m)

58,540

Shares Outstanding

58,883,272

Dividend Yield

PE Ratio

-2.07

Earnings Per Share (EPS)

-0.72

Revenue

63k

Net Profit

-42.67M

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator in... InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.inflarx.de

Headquarters

Jena, Deu

Founded

InflaRx NV is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IFRX. The last closing price for InflaRx NV was $1.48. Over the last year, InflaRx NV shares have traded in a share price range of $ 1.14 to $ 2.79.

InflaRx NV currently has 58,883,272 shares outstanding. The market capitalization of InflaRx NV is $87.15 million. InflaRx NV has a price to earnings ratio (PE ratio) of -2.07.

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress

JENA, Germany, Sept. 25, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today...

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases

JENA, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today...

InflaRx Announces Participation in September Investor Events

JENA, Germany, Aug. 27, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update

Hosted research and development (R&D) event focused on the differentiation of INF904 and its potential in addressing significant unmet needs in inflammation & immunology...

InflaRx to Report Second Quarter 2024 Results on August 8, 2024

JENA, Germany, Aug. 01, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...

InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases

JENA, Germany, July 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today...

InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)

JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Hosts R&D Event Highlighting the Promise of INF904

Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.0085	0.566666666667	1.5	1.58	1.4703	38079	1.5352499	CS
4	0.0485	3.32191780822	1.46	1.6	1.37	49431	1.50512679	CS
12	-0.0915	-5.71875	1.6	1.69	1.23	58540	1.49924722	CS
26	-0.0315	-2.04545454545	1.54	1.84	1.165	115225	1.47780411	CS
52	-1.2315	-44.9452554745	2.74	2.79	1.14	217290	1.54259981	CS
156	-1.2215	-44.7435897436	2.73	7.2499	0.7762	642198	3.92515522	CS
260	-0.7915	-34.4130434783	2.3	9.7	0.7762	610026	4.22919457	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
JTAIJet AI Inc	$ 0.1783 (92.55%)	332.76M
BLMZBloomZ Inc	$ 1.29 (80.37%)	63.25M
XHGXChange TED Inc	$ 0.289 (61.45%)	160.85M
WHLRWheeler Real Estate Investment Trust Inc	$ 13.0311 (33.52%)	5.06M
CRKNCrown Electrokinetics Corporation	$ 1.5001 (28.21%)	50.45M
GRTSGritstone bio Inc	$ 0.0775 (-60.94%)	54.91M
INHDInno Holdings Inc	$ 4.72 (-30.59%)	55.09k
MNTSMomentus Inc	$ 0.7434 (-29.87%)	19.1M
LKCOLuokung Technology Corporation	$ 1.95 (-26.42%)	93.96k
TXG10x Genomics Inc	$ 15.36 (-26.19%)	7.56M
JTAIJet AI Inc	$ 0.1783 (92.55%)	332.76M
XHGXChange TED Inc	$ 0.289 (61.45%)	160.85M
NVDANVIDIA Corporation	$ 134.3199 (1.26%)	92.76M
BLMZBloomZ Inc	$ 1.29 (80.37%)	63.25M
PEGYPineapple Energy Inc	$ 0.1291 (18.66%)	62.83M